Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:AKUSNASDAQ:EOLSNASDAQ:JANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.35+3.7%$3.28$2.71▼$4.73$618.48M1.5998,554 shs834,013 shsAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsEOLSEvolus$9.98+1.8%$11.57$8.67▼$17.82$631.87M1.11672,867 shs1.54 million shsJANXJanux Therapeutics$26.06+2.0%$29.16$22.52▼$71.71$1.54B3.24855,385 shs1.45 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+3.72%-4.56%+6.69%+1.21%+16.32%AKUSAkouos0.00%0.00%0.00%0.00%0.00%EOLSEvolus+1.84%-16.90%+4.61%-27.52%-21.73%JANXJanux Therapeutics+1.96%-12.52%-9.51%-27.83%-46.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.1366 of 5 stars3.50.00.00.03.32.50.6AKUSAkouosN/AN/AN/AN/AN/AN/AN/AN/AEOLSEvolus3.6966 of 5 stars3.51.00.03.52.02.50.6JANXJanux Therapeutics2.8394 of 5 stars3.52.00.00.04.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5064.18% UpsideAKUSAkouos 0.00N/AN/AN/AEOLSEvolus 3.00Buy$23.75137.98% UpsideJANXJanux Therapeutics 3.09Buy$95.25265.50% UpsideCurrent Analyst Ratings BreakdownLatest AKUS, ABUS, JANX, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/17/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/10/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/9/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/5/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/5/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.003/5/2025EOLSEvolusBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.003/3/2025JANXJanux TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.002/28/2025JANXJanux TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$62.00 ➝ $41.002/28/2025JANXJanux TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$75.00 ➝ $76.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M103.95N/AN/A$0.63 per share5.32AKUSAkouosN/AN/AN/AN/A$4.90 per shareN/AEOLSEvolus$266.27M2.42N/AN/A($0.36) per share-27.72JANXJanux Therapeutics$10.59M145.63N/AN/A$7.46 per share3.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$72.85M-$0.38N/AN/AN/A-1,137.65%-68.18%-51.55%5/15/2025 (Estimated)AKUSAkouos-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/AEOLSEvolus-$61.69M-$0.89N/AN/AN/A-22.33%-847.60%-22.15%7/30/2025 (Estimated)JANXJanux Therapeutics-$58.29M-$1.36N/AN/AN/A-463.91%-10.47%-9.86%N/ALatest AKUS, ABUS, JANX, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ABUSArbutus Biopharma-$0.09N/AN/AN/A$2.54 millionN/A5/6/2025Q1 2025JANXJanux Therapeutics-$0.42-$0.38+$0.04-$0.38$0.59 millionN/A3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million2/27/2025Q4 2024JANXJanux Therapeutics-$0.49-$0.36+$0.13-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AAKUSAkouosN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A7.027.02AKUSAkouosN/A17.3017.30EOLSEvolus20.582.472.23JANXJanux TherapeuticsN/A38.8038.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%AKUSAkouosN/AEOLSEvolus90.69%JANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%AKUSAkouos4.80%EOLSEvolus5.90%JANXJanux Therapeutics8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.48 million181.91 millionOptionableAKUSAkouos10336.94 million35.16 millionNot OptionableEOLSEvolus17064.48 million59.46 millionOptionableJANXJanux Therapeutics3059.17 million37.05 millionOptionableAKUS, ABUS, JANX, and EOLS HeadlinesRecent News About These CompaniesThe Manufacturers Life Insurance Company Purchases 32,917 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 12 at 3:45 AM | marketbeat.comFarallon Capital Management LLC Acquires Shares of 48,000 Janux Therapeutics, Inc. (NASDAQ:JANX)May 11 at 7:40 AM | marketbeat.comDriehaus Capital Management LLC Invests $27.61 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)May 11 at 6:50 AM | marketbeat.comCrestline Management LP Acquires New Position in Janux Therapeutics, Inc. (NASDAQ:JANX)May 11 at 6:30 AM | marketbeat.comAlgert Global LLC Acquires 40,489 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 9, 2025 | marketbeat.comJanux Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | businesswire.comCutter Capital Management LP Makes New $6.43 Million Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)May 8, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Down on Insider SellingMay 7, 2025 | marketbeat.comAlyeska Investment Group L.P. Raises Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)May 7, 2025 | marketbeat.comJanux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside PotentialMay 6, 2025 | finance.yahoo.comJanux Therapeutics begins phase 1b trial for prostate cancer therapyMay 6, 2025 | investing.comAvidity Partners Management LP Purchases 179,900 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 6, 2025 | marketbeat.comVoya Investment Management LLC Sells 25,547 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 6, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Down After Insider SellingMay 6, 2025 | americanbankingnews.comJanux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program UpdatesMay 5, 2025 | finance.yahoo.comJanux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside PotentialMay 5, 2025 | insidermonkey.comIs Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?May 5, 2025 | insidermonkey.comJanux Therapeutics (JANX) Expected to Announce Earnings on TuesdayMay 5, 2025 | americanbankingnews.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Ally Bridge Group NY LLCMay 4, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 39,855 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 4, 2025 | marketbeat.comRA Capital Management L.P. Acquires 1,200,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKUS, ABUS, JANX, and EOLS Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.35 +0.12 (+3.72%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$3.34 -0.02 (-0.45%) As of 05/12/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Akouos NASDAQ:AKUSAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Evolus NASDAQ:EOLS$9.98 +0.18 (+1.84%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$10.56 +0.58 (+5.85%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Janux Therapeutics NASDAQ:JANX$26.06 +0.50 (+1.96%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$26.25 +0.19 (+0.73%) As of 04:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
